南沙聚力细胞和基因产业，成立三大中心贯穿研发全链条

Core Insights - The "China Nansha Cell and Gene Industry Innovation Development Conference" was held in Guangzhou, focusing on cutting-edge technologies and industrial development in the cell and gene sector, attracting over a thousand enterprises [1] - The establishment of several key centers during the conference aims to promote the standardization and regulation of the cell and gene industry, addressing technical and management challenges [1][5] Industry Overview - Cell and gene therapy (CGT) is a rapidly developing frontier technology in biomedicine, with China's CGT market projected to exceed 8 billion RMB in 2024, primarily driven by CAR-T therapy, and expected to surpass 28.9 billion RMB by 2030 [2] - Global CGT market is forecasted to reach 76 billion USD by 2030, indicating significant growth potential [2] Regional Development - Guangzhou Nansha is positioned as a key area for the development of the biomedicine and health sector, leveraging its geographical, policy, and talent advantages [3] - The "Nansha Plan" includes tax incentives and regulatory reforms to support the growth of cell and gene therapy enterprises, creating a conducive environment for industry development [3] Ecosystem Building - Nansha has over 400 biomedicine enterprises, with more than 40 focused on cell and gene therapy, fostering collaboration among various entities to build a comprehensive industry ecosystem [3] - The release of the Nansha biomedicine and health industry map aims to facilitate project matching and address common challenges faced by enterprises [3] Regulatory Challenges - The safety, efficacy, compliance, and industrialization of cell and gene therapy remain areas requiring further exploration, with challenges including unclear responsibility, outdated regulations, and conflicts between safety and economic interests [4] - Experts suggest adopting established drug regulatory processes for cell and gene therapy to ensure safety and effectiveness, advocating for a balanced regulatory approach [4] Recent Developments - The launch of the Greater Bay Area Cell and Gene Therapy Industry Public Service Center and other key initiatives during the conference is expected to enhance the standardization and development of the industry [5] - Significant projects in gene therapy, immunotherapy, and stem cell pharmaceuticals were signed, with a total investment of approximately 500 million RMB and an expected annual output value of 1 billion RMB [6]